Insider · SEC Form 4 filer
Julian Baker
Companies
Where they file as an insider
Kodiak Sciences (KOD) Director, 10% owner Latest filing Sep 28, 2026
Celcuity (CELC) Insider Latest filing Jul 14, 2026
Kiniksa Pharmaceuticals International (KNSA) Director Latest filing May 29, 2026
KALA BIO (KALA) Insider Latest filing Oct 1, 2025
vTv Therapeutics (VTVT) Director Latest filing Sep 3, 2025
Madrigal Pharmaceuticals (MDGL) Director Latest filing Nov 21, 2023
Atreca (BCEL) Insider Latest filing Oct 19, 2023
Track record
Did their buys beat the typical stock?
Open-market buys54
Quarters checked 6 months later1
Beat the typical stock —
Quarters too new to check1
Too soon to tell. 1 quarter has finished so far. We show a record once 3 have.
Kodiak Sciences (KOD) Bought Sep 28, 2026 · $35M · 418,323 shares Too new Too new. Its 6-month check uses prices as of Mar 31, 2027.
Madrigal Pharmaceuticals (MDGL) Bought Nov 14–21, 2023 · $19.9M · 113,737 shares Beat typical Dec 31, 2023 $231.38 → Jun 30, 2024 $280.16 · +21.1% (typical stock −1.2%)
Each row is one stock in one quarter, however many buys it took. We take the stock's price at the end of that quarter and again 6 months later, and compare it with the typical stock over the same dates. Prices are quarter-end values from funds' 13F reports (the middle value across 3 or more funds), through Sep 30, 2026. Moves past 3 times up or down, mostly stock splits, are left out. How we tested this.
Past results. This is data, not advice.
Free weekly email
Each week's biggest real insider buys, cluster buys and fund moves, every one dated. One email a week. Unsubscribe in one click.